Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Understanding the value of points versus cash back helps you make smart financial choices. Compare both to see which is more beneficial.
28,655 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Researchers unveil an autonomous AI-driven worm that can learn and spread across networks without human input, signal...
Tech-led gains push major indices higher on June 9, 2026, with the S&P 500 and Nasdaq leading the rally as investors ...
Two industrial names sit at the center of the rare-earth supply story: MP Materials and TMC The Metals Company. This ...
Big goals don’t have to stay distant dreams. By reframing budgeting as a tool for empowerment, you can move from ‘can...
A mixed-bag forecast brings heat, rain, snow, and Arctic chills across the United States, with notable implications f...
U.S. stocks drift as a slate of fresh analyst calls prompts traders to reassess positions in consumer, tech and indus...
The rumor of a SpaceX IPO is stirring chatter across Wall Street and Main Street alike. If true, spacex could trigger...
Eli Lilly stands at a pivotal moment for investors. With a massive market-cap and a growing GLP-1 portfolio, the ques...
A retiree watched as a pop-up locked computer spiraled into a multi-month scam that drained more than $400,000 from h...
When celebrity headlines touch legal trouble abroad, ordinary people can still learn how to protect finances. This ar...
New data shows a broad wave of exits ahead as U.S. founders prepare to monetize stakes. The multi-year shift could re...